Adage Capital Partners
GTHX

Adage Capital Partners’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Adage Capital Partners’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-150,000
Closed -$458K – 963
2023
Q4 		$458K Buy
+150,000
New +$282K ﹤0.01% 783
2022
Q4 		– Sell
-346,000
Closed -$4.32M – 1058
2022
Q3 		$4.32M Buy
+346,000
New +$3.95M 0.01% 800

Other funds holding GTHX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Adage Capital Partners's GTHX Position: Q1 2024 in Review

Adage Capital Partners sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2024, closing a stake of 150,000 shares — an estimated $458K sold.

Adage Capital Partners first reported a position in GTHX in Q3 2022 and held it in 2 quarters. The position peaked at $4.32M in Q3 2022. 86 funds tracked by Wall St. Rank hold GTHX as of Q1 2024.

  • Adage Capital Partners reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Adage Capital Partners sold 150,000 G1 Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $458K.
  • Adage Capital Partners first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2022 and held it in 2 quarters.
  • Adage Capital Partners's G1 Therapeutics, Inc. Common Stock position peaked at $4.32M in Q3 2022.
  • 86 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Adage Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.